Effect of starting metformin on severe and long COVID-19 among people living with type 2 diabetes in England: a new user cohort study in OpenSAFELY-TPP

Introduction: Observational studies report lower COVID-19 mortality among metformin users, but most used prevalent-user designs comparing long-term survivors with heterogeneous controls. Randomised trials suggest little or no mortality effect. No large observational study has used a new-user design to estimate the effect of starting versus not starting metformin on severe and Long COVID outcomes in adults with type 2 diabetes (T2D). We aimed to estimate this effect on COVID-19-related hospitalisation or death, COVID-19 diagnoses, and Long COVID among adults with T2D in England. Research design

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.